- The FDA has granted regular approval to Gilead Sciences Inc’s (NASDAQ: GILD) Trodelvy (sacituzumab govitecan) for an aggressive and tough-to-treat type of breast cancer.
- The indication covers people with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.
- Initially, Trodelvy was granted accelerated approval by the FDA in April 2020 and, therefore, needed efficacy to be confirmed in further trials for full approval.
- The FDA based its full approval on results from the ASCENT trial.
- Trodelvy showed a statistically significant and clinically meaningful 57% reduction in the risk of disease worsening or death.
- Among all patients, median progression-free survival for patients who received Trodelvy was 4.8 months compared to 1.7 months in those who received chemotherapy.
- Moreover, treatment with Trodelvy was associated with a median overall survival of 11.8 months compared to 6.9 months for those who received chemotherapy.
- Side effects in more than 25% of patients who received Trodelvy included, but were not limited to, nausea, fatigue, anemia, constipation, rash, and decreased appetite.
- In March, the European Medicines Agency (EMA) validated the marketing application for sacituzumab govitecan-hziy for triple-negative breast cancer. The application is now under accelerated review by the EMA.
- Trodelvy, which Gilead had acquired as part of its $21 billion Immunomedics buyout, is an antibody-drug conjugate targeting Trop-2, a protein frequently expressed in multiple types of epithelial tumors.
- Price Action: GILD shares are up 0.79% at $66.12 in the premarket trading session on the last check Thursday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Be First to Comment